AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Gonadotropin-releasing hormone receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P30968

UPID:

GNRHR_HUMAN

Alternative names:

-

Alternative UPACC:

P30968; O75793; Q14D13; Q92644

Background:

The Gonadotropin-releasing hormone receptor (GnRH-R) plays a pivotal role in the reproductive system. It binds to GnRH, triggering the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through a G-protein-coupled phosphatidylinositol-calcium second messenger system. Its isoform 2 can inhibit GnRH-R signaling, showcasing the receptor's complex regulatory mechanisms.

Therapeutic significance:

GnRH-R's involvement in Hypogonadotropic hypogonadism 7, a condition marked by delayed or absent sexual maturation and low gonadotropin levels, underscores its therapeutic potential. Targeting GnRH-R could lead to novel treatments for reproductive disorders, including those with anosmia or normosmic idiopathic hypogonadotropic hypogonadism (nIHH), by modulating hormone release.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.